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Key Points
• Synthetic sulfated
glycopolymers bind to
EGF-like repeat 13 of
PEAR1, which leads
to Src- and PI3K-
dependent aggregation
of human platelets.
•GPIba supports
synthetic glycopolymer
activation of human and
mouse platelets, but the
predominant signaling
receptor in mice is
CLEC-2.
Fucoidansare sulfated fucose-basedpolysaccharides that activateplatelets andhavepro- and
anticoagulant effects; thus, they may have therapeutic value. In the present study, we show
that 2 synthetic sulfated a-L-fucoside-pendant glycopolymers (with average monomeric
units of 13 and 329) and natural fucoidans activate human platelets through a Src- and
phosphatidylinositol 3-kinase (PI3K)–dependent and Syk-independent signaling cascade
downstream of the platelet endothelial aggregation receptor 1 (PEAR1). Synthetic
glycopolymers and natural fucoidan stimulate marked phosphorylation of PEAR1 and Akt,
but not Syk. Platelet aggregation and Akt phosphorylation induced by natural fucoidan and
synthetic glycopolymers are blocked by a monoclonal antibody to PEAR1. Direct binding of
sulfated glycopolymers to epidermal like growth factor (EGF)–like repeat 13 of PEAR1 was
shown by avidity-based extracellular protein interaction screen technology. In contrast,
synthetic glycopolymers and natural fucoidans activate mouse platelets through a Src- and
Syk-dependent pathway regulated by C-type lectin-like receptor 2 (CLEC-2) with only a
minor role for PEAR1. Mouse platelets lacking the extracellular domain of GPIba and human
platelets treated with GPIba-blocking antibodies display a reduced aggregation response to
synthetic glycopolymers. We found that synthetic sulfated glycopolymers bind directly to
GPIba, substantiating that GPIba facilitates the interaction of synthetic glycopolymers with
CLEC-2 or PEAR1. Our results establish PEAR1 as the major signaling receptor for natural
fucose-based polysaccharides and synthetic glycopolymers in human, but not in mouse,
platelets. Sulfated a-L-fucoside-pendant glycopolymers are unique tools for further
investigation of the physiological role of PEAR1 in platelets and beyond.
Introduction
Marine fucoidans are heterogeneous fucose-rich sulfated polysaccharides derived from brown seaweed
and echinoderms. Fucoidans have a wide range of biological functions and potential medical
applications due to their anticancer, antimicrobial, and anti-inflammatory properties.1 In addition,
fucoidan polysaccharides have been shown to affect hemostasis,1 having both procoagulant2,3 and
anticoagulant4,5 actions. Fucoidans also have platelet-activating and -inhibiting properties, depending on
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their origin.5 The conflicting observations are explained by varying
chain length, branching, and degree of sulfation.5-8
The activation of platelets by sulfated polysaccharides of different
monosaccharide backbones has been investigated. Manne et al
reported that fucoidan from Fucus vesiculosus activates human and
mouse platelets through C-type lectin-like receptor 2 (CLEC-2),9
whereas a later study showed that higher concentrations also
activate GPVI in mouse platelets.10 On the other hand, the highly
sulfated heparin-like polysaccharide dextran sulfate, which has a
glucoside backbone, stimulates platelet aggregation simultaneously
through PEAR1 and CLEC-2.11
The multivalent nature of polysaccharides, in combination with their
complex and heterogenic structure, gives rise to multiple protein
interactions and complex mechanisms of platelet activation.7,8,12
For these reasons, we synthesized highly sulfated and unbranched
glycopolymers of different average chain lengths with fucoidan-
mimetic properties and compared these with natural fucoidan from
F vesiculosus.6,13,14 We show that, unexpectedly, these fucoidan-
like constructs induce human platelet activation predominantly via
PEAR1, facilitated by GPIba. In contrast, in mouse platelets, the
synthetic compounds induce platelet activation via CLEC-2, again
facilitated by GPIba.
Materials and methods
Chemicals and antibodies
Sulfated a-L-fucoside-pendant glycopolymers C329 (n 5 329
average monomeric units) and C13 (n 5 13 average monomeric
units), as well as biotinylated glycopolymers (average monomeric
units n 5 27), were synthesized as described.6,14 The sulfated
glycopolymers are described in more detail in supplemental
Materials and methods and supplemental Table 1. Fucoidan from
F vesiculosus$95% (#F8190) and dextran sulfate (#D8906) were
purchased from Sigma-Aldrich. Rhodocytin was purified from
Calloselasma rhodostoma venom, as described,15 and convulxin
was obtained from PENTAPHARM. The monoclonal antibody
(mAb) against CLEC-2 was raised as described.16 For a complete
list of reagents, see supplemental Materials and methods.
Human platelet preparation
This study was conducted in accordance with the Declaration of Helsinki.
Blood sampling was approved by the Regional Ethical Review Board in
Uppsala, Sweden (Dnr 2015/543). Heparinized blood (10 IU/ mL; LEO
Pharma) was drawn by venipuncture from healthy volunteers and
treated with acid-citrate-dextrose (71 mM citric acid, 85 mM sodium
citrate, 111 mM glucose) at a 1:5 ratio. Platelets were isolated using
2-step centrifugation and resuspended in Krebs–Ringer glucose
buffer with 0.05 U/mL apyrase and 1 mM CaCl2, as described.
6
Mouse platelet preparation
Platelet-specific CLEC-2–knockout mice (Clec1bfl/fl;PF4-Cre)17 and
hIL-4Ra/GPIba-Tg mice were bred as described.18 All procedures
were performed following United Kingdom Home Office approval
(PPL P0E98D513). Washed mouse platelets were pelleted from
harvested platelet-rich plasma by centrifugation at 500g for
9 minutes and otherwise prepared as described.19 Pear12/2 mice
were produced, and mouse platelets were isolated as previously
described.11 Animal experimental procedures were approved by the
local Ethics Committee of KU Leuven.
Platelet aggregation
Platelet aggregation was measured using a lumi-aggregometer
(Model 700; CHRONO-LOG) under stirring conditions at 37°C.
Human and mouse platelets were used at concentrations of 2.5 3
108/mL and 2 3 108/mL, respectively.
Intracellular Ca21 mobilization
Platelet-rich plasma was incubated with 4 mM Fura-2, AM (#F0888;
Sigma-Aldrich),20 and Ca21 was measured as described in
supplemental Materials and methods.
Western blotting
Stimulation of washed human platelets (2.5 3 108/mL) and murine
platelets (5 3 108/mL) was performed at 37°C. Reactions were
stopped using lysis buffer.6,21 Immunoprecipitation was performed
according to the manufacturer’s instructions using a Pierce Classic
IP Kit (#26146; Thermo Fisher Scientific) in the presence of
protease and phosphatase inhibitor cocktails. The level of
chemiluminescence and fluorescence was registered using an
Odyssey Fc imaging system (LI-COR). Densitometry of the bands
was performed using Image Studio software version 3.1 (LI-COR).
Results are presented in arbitrary units.
Recombinant protein expression
Plasmid design and expression of pentameric b-lactamase–
containing proteins with C-terminal His6 tag were performed.22
Further details are provided in supplemental Materials and
methods.
AVEXIS
An avidity-based extracellular protein interaction screen (AVEXIS)
was performed.22 Further details are provided in supplemental
Materials and methods.
Statistics
Data analysis was performed using GraphPad Prism 6. Significance
was calculated using 1-way ANOVA with the Bonferroni correc-
tion for multiple comparisons. P , .05 was considered significant.
The results are presented as mean 6 standard error of the mean
(SEM).
Results
Synthetic glycopolymers cause concentration-dependent
aggregation of human and mouse platelets
In this study, the sulfated a-L-fucoside-pendant glycopolymers
C329 (average monomeric units n 5 329) and C13 (average
monomeric units n 5 13) induce concentration-dependent aggre-
gation (Figure 1). Maximal magnitude of aggregation of human and
mouse platelets took place at ;0.2 mM C329 and ;4.1 mM C13,
which represents a weight dose of 30 mg/mL in both cases. Molar
concentrations were calculated based on the average Mn calc, as
described in supplemental Table 1. Natural fucoidan has a much
larger molecular weight spread and unpredictable branching
compared with the synthetic compounds6,8,13 and was used at a
comparable weight dose (30 mg/mL) in this study.
The concentration-effect curves in Figure 1A reveal that C329 is
more potent at causing aggregation in human (Figure 1B) and
mouse (Figure 1C) platelets when compared on a molar basis. This
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can be explained by the almost 30 times greater number of average
monomeric units per molecule in C329 relative to C13. Platelet
aggregation in mice (Figure 1C) is initiated after a prominent shape
change that is not present in human platelets (Figure 1B). Figure 1D
shows a comparison of aggregation in human platelets caused by
30 mg/mL fucoidan from F vesiculosus and dextran sulfate. The
fucoidan dose used in this study (30 mg/mL) was selected based
on dose-response experiments shown in supplemental Figure 1A.
A dose of 30 mg/mL is 10-fold higher than the lowest dose that
induces maximal platelet aggregation. Fucoidan from F vesiculosus
(30 mg/mL) causes time-dependent intracellular phosphorylation in
isolated platelets, as shown in supplemental Figure 1B.
Synthetic glycopolymers and natural fucoidan do not
activate Syk in human platelets
In human platelets, the synthetic glycopolymer C329 (0.2 mM), at
a concentration that gives rise to maximal aggregation and the
CLEC-2 agonist rhodocytin (50 nM), stimulates distinct patterns
and time courses of protein tyrosine phosphorylation (Figure 2A).
Rhodocytin stimulated tyrosine phosphorylation of multiple proteins
with a delay of 20 seconds, including prominent bands of 36, 70-80,
and 120 kDa. The increase in phosphorylation was transient. In
contrast, C329 stimulated a distinct pattern of tyrosine phosphor-
ylation at 20 seconds that was sustained for up to 5 minutes,
including a prominent band ; 150 kDa.
We used phosphospecific antibodies to further probe the increase
in phosphorylation. Rhodocytin induced phosphorylation of Syk on
tyrosines 348 and 525/526 and LAT on tyrosine 191 (Figure 2A). In
contrast, neither synthetic glycopolymer C329 nor natural fucoidan
stimulated a significant increase in phosphorylation of Syk on these
residues (Figure 2Bi-iii). In addition, wewere unable to detect an increase
in tyrosine phosphorylation of CLEC-2 in human platelets in response to
synthetic glycopolymers and natural fucoidans (data not shown).
These results show that the synthetic glycopolymers stimulate
marked phosphorylation of a major band of 150 kDa in human
platelets independent of CLEC-2.
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Figure 1. Potency of synthetic glycopolymer–induced platelet aggregation is chain length dependent. (A) Isolated human and mouse platelet aggregation was
measured in response to increasing molar concentrations of synthetic glycopolymers C329 and C13. Maximal increase in light transmission is presented as mean 6 SEM
(n 5 3 experiments). Original traces of C329-induced (Bi) and C13-induced (Bii) human platelet aggregation and C329-induced (Ci) and C13-induced (Cii) mouse platelet
aggregation. (D) Comparison of equal weight doses (30 mg/mL) of fucoidan from F vesiculosus (FV) and dextran sulfate (DS).
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Synthetic glycopolymers and natural fucoidan
activate human platelets via a Src-dependent and
Syk-independent pathway
It has previously been described that signaling by CLEC-2 is
dependent on Src and Syk tyrosine kinases.9,23 The pan Src family
kinase inhibitor PP2, its inactive analog PP3, and the Syk inhibitor
BAY 61-3606 were used to investigate the role of Src and Syk
tyrosine kinases in platelet activation. PP2 (10 mM), but not its
inactive analog PP3 (10 mM) or BAY 61-3606 (1 mM), blocked
aggregation to C13, C329, fucoidan from F vesiculosus, and
dextran sulfate, whereas BAY 61-3606 (1 mM) blocked aggregation
to rhodocytin and convulxin (Figure 3). The Src inhibitor PP2 did not
block aggregation by thrombin (0.1 U/mL). Likewise, synthetic
glycopolymer-induced human platelet aggregation was not
inhibited in control experiments by a second Syk inhibitor (PRT-
060318, 10 mM) (data not shown).
Platelet activation by CLEC-2 and GPVI gives rise to robust
elevation of intracellular Ca21. In contrast, the activation of platelets
by dextran sulfate is associated with only a small change in
intracellular Ca21,24 which was confirmed in this study (supple-
mental Figure 2A). Similarly, C13, C329, and fucoidan from
F vesiculosus induced a minimal increase in intracellular Ca21 in
contrast to the marked increase induced by convulxin (supplemen-
tal Figure 2A). The convulxin-induced peak rise in cytosolic Ca21
was not significantly altered by preincubation of synthetic glyco-
polymers or sulfated polysaccharides (supplemental Figure 2Aii),
confirming platelet viability. Neither synthetic glycopolymer C329
nor natural fucoidan caused phosphorylation of PLCg2 on tyrosine
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Figure 2. Differences in human platelet tyrosine phosphorylation patterns comparing synthetic glycopolymers with rhodocytin, the snake venom
agonist for CLEC-2. (A) Isolated platelets were stimulated using the synthetic glycopolymer C329 (0.2 mM) or the CLEC-2 agonist rhodocytin (R; 50 nM)
for 0.3, 1, 2, or 5 minutes. Control (Ctrl) sample was treated with an equal volume of H2O. Samples were analyzed by sodium dodecyl sulfate–polyacrylamide gel
electrophoresis, followed by western blot. Membranes were stained for tyrosine phosphorylation (4G10), p-Syk Tyr525/526, p-Syk Tyr348, and LAT Tyr191. (Bi)
Phosphorylation patterns of p-Syk Tyr525/526, p-Syk Tyr348, and LAT Tyr191 were also compared for fucoidan from F vesiculosus (FV; 30 mg/mL). Quantification
of Syk (Bii) and LAT (Biii) phosphorylation. Graphs represent data from 3 or 4 experiments, and densitometry quantification is presented in arbitrary units (a.u.) as
mean 6 SEM. Control 5 1 a.u. *P , .05 vs 0.3-minute control.
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1217. On the other hand, rhodocytin induced prominent phos-
phorylation after 1 minute (supplemental Figure 2B).
These results show that the synthetic glycopolymers and natural
fucoidan activate human platelets via a Src-dependent and
Syk-independent pathway that is similar to that described for the
sulfated glucoside polysaccharide dextran sulfate.24
Synthetic glycopolymers and natural fucoidan
stimulate PI3K/Akt signaling in human platelets
The sulfated glucoside polysaccharide dextran sulfate has been
reported to stimulate aggregation of human platelets via PI3K-
dependent phosphorylation of Akt,11 which was confirmed in this
study. Similarly, aggregation induced by synthetic glycopolymers
C329 andC13 and natural fucoidanwas abolished by the structurally
distinct PI3K inhibitors, wortmannin and LY294002, as shown in
the example traces (Figure 4Ai) and in the bar graph (Figure 4Aii).
Both inhibitors also reduced the response to convulxin (Figure 4Aii),
a well-described inducer of GPVI–Fc receptor g-chain and Syk
signaling.25,26 In contrast, the maximal level of aggregation induced
by the G protein–coupled PAR1 agonist peptide SFLLRN (single
amino acid code) was unaltered in the presence of either inhibitor
(Figure 4Aii). The selected concentrations of wortmannin (1 mM) and
LY294002 (50 mM) used in this study abolish PI3K-induced Akt
phosphorylation.27-29 As shown in Figure 4B, synthetic glycopolymer
C329, natural fucoidan, and dextran sulfate, but not rhodocytin,
stimulated marked Akt phosphorylation on serine 473 after 1 minute.
These results demonstrate that synthetic glycopolymers, as well as
sulfated fucoside and glucoside polysaccharides, stimulate human
platelet aggregation through a PI3K-dependent pathway that
involves phosphorylation of Akt.
Synthetic glycopolymers and natural fucoidans
activate human platelets via PEAR1
Dextran sulfate has been reported to stimulate platelet activation via
the surface glycoprotein receptor PEAR1.11 Therefore, studies
were designed to investigate whether PEAR1 is a receptor for
synthetic glycopolymers and natural fucoidans. C13, C329, fucoidan
from F vesiculosus, and dextran sulfate all stimulated marked
phosphorylation of PEAR1, whereas neither convulxin nor rhodocytin
induced phosphorylation (Figure 5A). Collagen has previously been
shown to induce PEAR1 phosphorylation, but only after platelet–
platelet contact has been established.30,31 In contrast, in the
present study we measured phosphorylation after 20 seconds,
which is too early for secondary aggregation-dependent PEAR1
phosphorylation. Hence, neither rhodocytin nor convulxin triggered
PEAR1 phosphorylation at 20 seconds, whereas the sulfated
glycopolymers and polysaccharides did so substantially, as a result
of direct PEAR1 activation. Furthermore, as shown in Figure 5B, a
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Figure 3. Functional consequence of Syk and Src inhibition in synthetic glycopolymer– and fucoidan-stimulated human platelets. Isolated platelets were incubated for
5 minutes with the Syk inhibitor BAY 61-3606 (1 mM) or the Src inhibitor PP2 (10 mM). Samples were stimulated using the CLEC-2 agonist rhodocytin (R; 50 nM), dextran sulfate
(DS; 30 mg/mL), fucoidan from F vesiculosus (FV; 30 mg/mL) or the glycopolymers C329 (0.2 mM) or C13 (4.1 mM) and analyzed by aggregometry. The GPVI agonist convulxin (CVX;
10 ng/mL) and thrombin (Thr; 0.1 U/mL) were used as controls. (A) Original traces. (B) Quantification of maximal aggregation. The inert analog PP3 (10 mM) was used as a control against
PP2. Aggregation was measured as increases in light transmission. All samples contained ,0.05% dimethyl sulfoxide. Representation of n 5 3 experiments. *P , .05, treatment vs control.
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mAb to PEAR1 inhibited platelet aggregation by C13, C329,
F vesiculosus fucoidan, and dextran sulfate but had no effect on
platelet aggregation to rhodocytin. In addition, preincubation with
the PEAR1 mAb significantly reduced Akt phosphorylation induced
by C13, C329, and F vesiculosus fucoidan (Figure 5C).
AVEXIS, a screening method for protein interactions, was used to
investigate potential PEAR1 binding sites of synthetic sulfated glycopol-
ymers. We have previously shown that high-affinity immunoglobulin E
receptor a (FceR1a), the natural ligand to PEAR1, binds directly to
epidermal-like growth factor (EGF) repeat 13 of the receptor.22 We
investigated whether this was also the case for sulfated glycopolymers.
Binding was compared for EGF-like repeats 1 to 12, 13, and 12 to 14 of
PEAR1. In Figure 5D, we show that sulfated biotinylated glycopolymers
(SPs) bind to EGF-like repeats 13 and 12 to 14, but not to 1 to 12. This
indicates that the PEAR1 EGF-like repeat 13 is sufficient to bind sulfated
glycopolymers. The nonsulfated biotinylated glycopolymers (NSPs)
followed a similar, but weaker, binding pattern. An irrelevant protein,
JAM1, was used as negative-control prey.
Taken together, these results confirm that synthetic sulfated a-L-
fucoside-pendant glycopolymers bind to and activate human
platelets through PEAR1.
PEAR1 is activated by synthetic glycopolymers in
murine platelets but is not essential for aggregation
Murine platelet aggregation by dextran sulfate has been described to
involve PEAR1 and CLEC-2.11 In line with this, aggregation induced
by synthetic glycopolymers is inhibited at lower concentrations in
PEAR1-deficient mice (Figure 6A). However, higher concentrations
of synthetic glycopolymers can overcome the lack of PEAR1 and
induce platelet aggregation through a pathway that is blocked by the
Syk inhibitor BAY 61-3606 (data not shown). This indicates that
synthetic glycopolymers can activate PEAR1 in murine platelets but
that the receptor is not essential for synthetic glycopolymer-induced
aggregation, because the response is overcome at higher concen-
trations. Furthermore, the 2 synthetic glycopolymers induce PEAR1
phosphorylation in murine platelets (data not shown).
Synthetic glycopolymer-induced platelet aggregation
is inhibited in CLEC-2–deficient mice
It has been reported that fucoidan activates mouse platelets through
CLEC-2 and GPVI, as shown by abolition of activation in mice
deficient in both receptors.9,10 At low concentrations, the response is
abolished in mice deficient in CLEC-2.9 Therefore, the activation of
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Figure 4. The PI3K/Akt signaling pathway is essential for human platelet activation by synthetic glycopolymers and natural fucoidan. (Ai) Original traces of
platelet aggregation by C329 (0.2 mM), C13 (4.1 mM), fucoidan from F vesiculosus (FV; 30 mg/mL), and dextran sulfate (DS; 30 mg/mL) in the presence or absence of
wortmannin (1 mM) or LY294002 (50 mM). (Aii) Quantification of human platelet aggregation. PAR1 activating peptide SFLLRN (10 mM) and GPVI agonist convulxin
(CVX; 10 ng/mL) were used as controls. All samples contained ,0.05% dimethyl sulfoxide. Maximal increase in light transmission is presented as mean 6 SEM (n 5 3 or 4
experiments). *P , .05, PI3K inhibitors vs control. (B) Isolated platelets were stimulated using synthetic glycopolymer C329 (0.2 mM), FV (30 mg/mL), DS (30 mg/mL), or the
CLEC-2 agonist rhodocytin (R; 50 nM). Control (Ctrl) sample was treated with an equal volume of H2O. Reactions were stopped at 0.3, 1, or 2 minutes, and samples were
analyzed by sodium dodecyl sulfate–polyacrylamide gel electrophoresis, followed by western blot. Graph represents n 5 3 experiments; densitometry quantification is
presented in arbitrary units (a.u.) as mean 6 SEM. Control 5 1 a.u. *P , .05, treatment vs 0.3-minute control.
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CLEC-2 or GPVI could explain the inhibitory effect of the Syk inhibitor
BAY 61-3606 during aggregation of wild-type or Pear12/2 platelets.
C13 and C329 induce a prominent platelet shape change in mouse
platelets (in contrast to human platelets), as indicated by the
decrease in light transmission prior to the primary aggregation
phase (Figure 6). In CLEC-2–deficient mice, platelet aggregation to
C13 and C329 was markedly inhibited but not abolished (Figure 6B).
Platelets deficient for CLEC-2 were still responsive to collagen
(10 mg/mL), indicating platelet functionality (Figure 6Bii). The
rapid shape change observed in wild type platelets was absent in
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Figure 5. Synthetic glycopolymers and sulfated polysaccharides cause human platelet aggregation via PEAR1 by direct binding to EGF-like repeats 13 and
12 to 14 of PEAR1. (A) Aliquots of platelet suspension were stimulated with convulxin (CVX; 10 ng/mL), rhodocytin (R; 50 nM), dextran sulfate (DS; 30 mg/mL), fucoidan
from F vesiculosus (FV; 30 mg/mL), C329 (0.2 mM), or C13 (4.1 mM) for 20 seconds, after which immunoprecipitation for PEAR1 was performed. Samples were analyzed by
sodium dodecyl sulfate–polyacrylamide gel electrophoresis, followed by western blot. Membranes were probed with the pan tyrosine phosphorylation antibody 4G10. Control
sample was treated with an equal volume of H2O instead of agonist. *P , .05, treatment vs control. (B) Aggregation was measured as the increase in light transmission using
isolated platelets. Isolated platelets were incubated for 2 minutes with anti-PEAR1 antibody (0.3 mg/mL) or matching isotype control (0.3 mg/mL) and subsequently stimulated
with C329, C13, FV, or DS. R was used as control. All samples contain ,0.0002% sodium azide. (C) Isolated platelets were preincubated with anti-PEAR1 antibody
(0.3 mg/mL) or corresponding isotype control (0.3 mg/mL) for 2 minutes. Samples were stimulated with DS, FV, C329, or C13 for 1 minute. Samples were analyzed by sodium
dodecyl sulfate–polyacrylamide gel electrophoresis, followed by western blot. Representation of n 5 3 experiments. *P , .05, isotype vs PEAR1 antibody. (Di) Illustration of
PEAR1 and schematic overview of the EGF-like repeats that were analyzed by AVEXIS. The red EGF-like repeat is number 13, which is sufficient to bind sulfated synthetic
glycopolymers. (Dii) Detection of PEAR1–glycopolymer interaction by AVEXIS. SPs and NSPs were plate immobilized, acting as a bait for EGF-like repeats 1 to 12, 13, and
12 to 14. Absorbance for b-lactamase activity was measured at 485 nm. Data are mean 6 SEM (n 5 3 experiments). *P , .05, SPs vs NSPs.
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CLEC-2–deficient platelets (Figure 6Bi), resembling aggregation
in human platelets (Figures 1B, 3A, 4Ai, and 5B). The synthetic
glycopolymer C329 stimulated tyrosine phosphorylation of CLEC-2
in wild-type and Pear12/2 mouse platelets (data not shown).
The results show that, in contrast to human platelets, CLEC-2 (and
not PEAR1) is the major signaling receptor for synthetic fucoidans
in mouse platelets. The observation that the response to a high
concentration of the synthetic fucoidans is blocked by BAY 61-3606
suggests that the CLEC-2–independent aggregation is mediated
by GPVI, as previously shown,10 rather than by PEAR1. The loss of
response to low concentrations of the synthetic fucoidans in PEAR1-
deficient mice is most likely due to synergy with Syk activation or an
adhesive effect.
Synthetic glycopolymer–induced platelet aggregation
is supported by GPIba
The von Willebrand factor receptor GPIba has previously been
hypothesized as a possible binding target for the sulfated poly-
saccharide dextran sulfate.24 In addition, it has been shown that
O-linked carbohydrates are of importance in von Willebrand factor–
GPIba binding.32 In the current study, we show that sulfated synthetic
glycopolymers bind to the full-length extracellular domain of GPIba,
whereas nonsulfated glycopolymers do not (Figure 7A). The contribu-
tion of GPIba to human platelet activation by synthetic glycopolymers
was evaluated using GPIba-blocking antibodies. This led to the
demonstration that 2 antibody clones to GPIba reduced, but did not
block, aggregation to synthetic glycopolymers (Figure 7Bi-ii). Clone SZ2
binds the anionic region of the receptor, andHIP1 binds the leucine-rich
repeat (LRR) region.33 Thrombin was used as a control, because it has
been shown to be inhibited, in part, by anti-GPIba antibodies.34
The effect of glycopolymer-induced platelet aggregation was further
assessed in hIL-4Ra/GPIba-Tg mice, which lack the extracellular
domain of GPIba.18 As shown in Figure 7Ci and 7Cii, platelet
aggregation was significantly reduced in mice platelets without
the extracellular domain of GPIba. On the other hand, shape
change occurred prior to aggregation of hIL-4Ra/GPIba-Tg mouse
platelets (Figure 7Ci-ii).
These results indicate a role for GPIba in human and mouse platelet
aggregation by synthetic glycopolymers.
Discussion
This study shows that synthetic sulfated a-L-fucoside-pendant
glycopolymers and natural highly purified fucoidan polysaccharides
A
100 %
0 %
Lig
ht
 tr
an
sm
iss
ion
Wild type
2 min
Wild type
Pear1-/-Pear1
-/-
C329
[0.03 M]
C13
[0.7 M]
0
50
100
0.03
* *
Wild-type
Pear1-/-
C329 [M] C13 [M]
0.2 0.7 4.1
Lig
ht
 tr
an
sm
iss
ion
 (%
)
B
100 %
0 %
Lig
ht
 tr
an
sm
iss
ion
5 min
Wild type
Wild type
Clec1bfl/fl;PF4-Cre
Clec1bfl/fl;PF4-Cre
C329
[0.2 M]
C13
[4.1 M]
*
*
C329 C13 Collagen
0.2 M 4.1 M 10 g/ml
Lig
ht
 tr
an
sm
iss
ion
 (%
)
0
50
100 Wild-type
Clec1bfl/fl;PF4-Cre
i
ii ii
i
Figure 6. Mouse platelets deficient in PEAR1 (Pear12/2) still aggregate to high concentrations of synthetic glycopolymers, whereas CLEC-2–deficient
platelets (Clec1bfl/fl;PF4-Cre) do not. Murine platelets were analyzed for platelet aggregation upon stimulation by C329 and C13. (Ai) Original traces of PEAR1-deficient
platelets compared with wild-type platelets stimulated with C329 (0.03 mM) and C13 (0.7 mM). (Aii) Quantification of maximal aggregation. Representation of 3 to 5
experiments. *P , .05, wild-type vs Pear12/2 mice. (Bi) Original traces of CLEC-2–deficient platelets compared with wild-type platelets stimulated by C329 (0.2 mM) and
C13 (4.1 mM). (Bii) Quantification of maximal aggregation within 10 minutes. Collagen (10 mg/mL) was used as a control for Clec1bfl/fl;PF4-Cre platelet reactivity. Representation
of 3 experiments. *P , .05, wild-type vs Clec1bfl/fl;PF4-Cre mice.
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activate human platelets through PEAR1. Synthetic glycopolymers
and natural fucoidan of high purity from F vesiculosus give rise to
tyrosine phosphorylation patterns that differ significantly from those of
the CLEC-2 agonist rhodocytin. Naturally occurring fucoidans from
seaweed primarily consist of highly sulfated fucose polysaccharides
but may also contain other types of sugars and contaminants. Even
the season of harvest can affect the composition.1,7,8,12,35 These
factors may contribute to previously published observations show-
ing a role for CLEC-2 in activation of human platelets by fucoidan of
80% purity from F vesiculosus.9
Our data show that PEAR1 is the critical receptor causing human
platelet activation by synthetic sulfated glycopolymers and natural
fucoidan polysaccharides. PEAR1 is a transmembrane receptor
of the EGF-like domain family. It has 15 EGF-like repeats and is
highly expressed on endothelial cells and platelets. In endothelial
cells, PEAR1 is a modulator of cell proliferation during
neoangiogenesis.36 With respect to its role in platelets, genome-
wide analysis has identified genetic variations in PEAR1 associated
with altered responses during platelet aggregation by various
agonists.37 Certain PEAR1 gene haplotypes were strongly
associated with human platelet integrin aIIbb3 activation and
P-selectin expression upon GPVI stimulation, and, in various
ethnicities, several PEAR1 single-nucleotide polymorphisms have
been associated with increased platelet aggregation for 1 allele,
coupled to a higher platelet PEAR1 expression.38-40 Also in
platelets, PEAR1 clustering triggers its phosphorylation via cSrc,
recruitment of the p85 PI3K chain, and PI3K-mediated Akt
phosphorylation.30 Thus, PEAR1 facilitates platelet–platelet con-
tact31 and stabilizes platelet aggregates.30 However, the absence
of PEAR1 in mice did not significantly affect hemostasis, indicating
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Figure 7. Synthetic glycopolymers require GPIba to induce full aggregation in murine and human platelets. (A) Detection of GPIba–glycopolymer interaction by
AVEXIS. SPs and NSPs were plate immobilized, acting as a bait for the full-length extracellular domain of GPIba. CD200 was used as a negative control protein. Absorbance
for b-lactamase activity was measured at 485 nm, presented as mean 6 SEM (n 5 3 experiments). *P , .05. (Bi) Human platelet aggregation. Platelet aliquots were treated
with anti-GPIba antibody SZ2 (0.3 mg/mL), HIP2 (0.3 mg/mL), or isotype control (0.3 mg/mL) for 2 minutes before stimulation by C329 or C13. (Bii) Quantification of maximal
aggregation within 10 minutes. Thrombin was used as a control at 0.3 and 0.2 U/mL. Increase in light transmission is presented as mean 6 SEM (n 5 3 experiments).
*P , .05. (Ci) Mouse platelet aggregation. Murine wild-type platelets and transgenic mouse platelets deficient in GPIba extracellular domain (hIL4-Ra/GPIba-Tg) were
stimulated using synthetic glycopolymers C329 (0.2 mM) and C13 (4.1 mM). (Cii) Quantification of maximal increase in light transmission within 10 minutes. Collagen (10 mg/ml)
was used as a control for platelet viability. *P , .05, wild-type vs hIL4-Ra/GPIba-Tg mice.
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species differences.41 Yet, the exact physiological role of PEAR1 in
human hemostasis remains to be clarified. The synthetic glycopol-
ymers in this study represent unique tools for further investigating
the physiological role of PEAR1.
The high-affinity immunoglobulin E receptor a (FceR1a) has been
identified as a natural ligand for PEAR1.22 FceR1a is highly
glycosylated42 and, similarly to the sulfated glycopolymers, binds to
EGF-like repeat 13 of PEAR1, which was shown using AVEXIS
technology. However, the significance of FceR1a glycosylation
in the binding to, and activation of, PEAR1 remains to be
ascertained. The full-length PEAR1 receptor has weaker binding
to the sulfated glycopolymers compared with the shorter EGF-
like repeats 13 and 12 to 14 (data not shown). This may be
caused by steric hindrance due to the size of the full-length
PEAR1 receptor, such that EGF-like repeat 13 may not be able
to reach the sulfated glycopolymers.
The synthetic glycopolymers and natural fucoidan activate CLEC-2
in mouse platelets, inducing Src and Syk signaling in agreement
with a previous study using an 80% pure preparation of fucoidan
from F vesiculosus.9 Dextran sulfate activates mouse platelets via
PEAR1 and CLEC-2.11 The sulfated synthetic glycopolymers used
in this study cause murine platelet aggregation mainly via CLEC-2;
however, the synthetic glycopolymers cause phosphorylation of
PEAR1, but the receptor is not essential for aggregation at higher
concentrations of the compounds. On the contrary, in human
platelets, PEAR1 is essential for synthetic glycopolymer– and
natural fucoidan–induced aggregation. The demonstration of a
clear difference between man and mouse in terms of the
mechanism of platelet activation may reflect the large difference
in receptor density. Human platelets express ;2000 to 400043
copies of CLEC-2, whereas the mouse counterparts express
;41 000 copies.44 Another difference between human and mouse
platelet aggregation by synthetic glycopolymers is the lack of shape
change in human platelets. Shape change is primarily regulated by
increases in cytosolic calcium or activation of the G12/13 family of
heterotrimeric G proteins.45 Hence, the lack of shape change upon
synthetic glycopolymer stimulation in human platelets is most likely
due to the absence of Syk/LAT/PLCg2 signaling and, subsequently,
the minimal increase in cytosolic Ca21 or G protein activation
(Figure 2; supplemental Figure 2).
Our study also shows that the extracellular domain of GPIba is
important in synthetic glycopolymer–induced aggregation of murine
and human platelets. The extracellular N-terminal region of GPIba
contains several LRRs, which regulate binding to the von
Willebrand factor A1 domain. By blocking the curved concave face
of the LRRs, von Willebrand factor A1–GPIba interaction can be
inhibited.46 Inhibiting binding to the LRR region of human GPIba
with the antibody clone HIP1, which binds to an epitope in the
vicinity of the second LRR,47 or through loss of the extracellular
domain of GPIba in mouse platelets reduces, but does not
block, aggregation to synthetic glycopolymers. This indicates that
activation of PEAR1 in human platelets or CLEC-2 in mouse
platelets is potentiated by binding to GPIba but is not dependent on
this interaction, because the response is reduced but not blocked.
This can be explained through an avidity effect in which binding of
the synthetic glycopolymers to GPIba facilitates the interaction with
PEAR1 or CLEC-2. Binding to GPIba may also potentially generate
intracellular signals that synergize with those from PEAR1 or
CLEC-2; however, on their own, these are insufficient to mediate
activation of human platelets, because an antibody to PEAR1
abrogates aggregation. Thus, we propose that the short and long
synthetic glycopolymers used in this study induce platelet activation
through clustering of GPIb1a to PEAR1 (human) or CLEC-2
(mouse). The species difference can be explained by different levels
of CLEC-2 in human and mouse platelets, as discussed above. The
receptor density of PEAR1 is lower than CLEC-2 in both species.
Mouse platelets express ;3100 receptor44 copies of PEAR1,
whereas human platelets contain ;1800 copies.43 Therefore, the
PEAR1 preference in humans may also be due to differences in
glycopolymer–protein affinity between the 2 receptors.
We propose that electrostatic interactions mediated by binding of
the negatively charged fucoidans and synthetic glycopolymers to
positively charged residues in PEAR1 and CLEC-2 play a critical
role in mediating receptor binding and activation. Patterns of basic
amino acid (lysine, arginine, and histidine) clustered within protein
sequences have been shown to affect strength and specificity of
binding of glycosaminoglycans, such as heparin and heparan
sulfate.48,49 Our data show that an a-L-fucoside-pendant glyco-
polymer of ;13 monosaccharide residues causes full platelet
aggregation. For heparin binding to heparin cofactor II, a minimum
of 13 monosaccharide residues is required,50 and heparin binding
of antithrombin III relies on a specific sequence of 5 monosac-
charides.51 Heparin also binds to positively charged amino acid
regions within the heparin-binding EGF-like growth factor.52
Variable lymphocyte receptors containing LRRs also recognize
short trisaccharides on red blood cells.53 Exactly how many fucose
monosaccharide residues are required for inducing PEAR1/GPIba/
CLEC-2 aggregation or receptor clustering remains unexplored.
The longer synthetic glycopolymer C329 can induce full platelet
aggregation when used at much lower molarity than the short
synthetic glycopolymer C13 (Figure 1). The length-dependent
concentration-response curve shift may be attributed to the ability
to cross-link multiple receptors.
In PEAR1, basic amino acids are spread throughout the EGF repeat
sequence. However, EGF-like repeats 13 and 14 are the only
repeats that contain 2 consecutive positively charged amino
acids.31 Electrostatic interactions have previously been shown to
play a critical role in the activation of CLEC-2 by podoplanin. The
podoplanin extracellular domain contains 3 platelet aggregation-
stimulating (PLAG) domains with the sequence EDXXXT/S (single
amino acid code). Sialyation of the serine or threonine is critical for
platelet activation.54,55 Crystallization of a glycopeptide encom-
passing PLAG2 and PLAG3 with CLEC-2 has identified 2 sites of
electrostatic interaction between the DXXXT/S sequence and 4
arginines in CLEC-2.56 Future studies using advanced computer
modeling and crystallography may provide deeper insights on
carbohydrate–protein interactions.
In conclusion, we propose that synthetic glycopolymers and
natural fucoidan activate human platelets through cross-linking
of PEAR1 and GPIba, which is largely governed through an
electrostatic interaction. In mouse platelets, fucoidans induce
activation mainly through CLEC-2 and GPIba, most likely due to
the much greater level of expression compared with human
platelets. Synthetic sulfated a-L-fucoside-pendant glycopolymers
represent novel reagents for studying the functional role of PEAR1
in platelets.
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